BETHESDA, Md., Dec. 19, 2017 /PRNewswire/ — Northwest Biotherapeutics (OTCQB: NWBO) — (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is commencing a general solicitation Regulation D offering to…
